source
- Fulcrum Therapeutics considers sale after FDA blocks sickle cell drug developmentFulcrum Therapeutics announced it is undertaking a strategic review that could lead to a sale after its lead sickle cell candidate, pociredir, was effectively blocked by the FDA. The agency cited…